{
    "paper_id": "PMC7228377",
    "metadata": {
        "title": "Development of epitope\u2010based peptide vaccine against novel coronavirus 2019 (SARS\u2010COV\u20102): Immunoinformatics approach",
        "authors": [
            {
                "first": "Manojit",
                "middle": [],
                "last": "Bhattacharya",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Ashish",
                "middle": [
                    "R."
                ],
                "last": "Sharma",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Prasanta",
                "middle": [],
                "last": "Patra",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Pratik",
                "middle": [],
                "last": "Ghosh",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Garima",
                "middle": [],
                "last": "Sharma",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Bidhan",
                "middle": [
                    "C."
                ],
                "last": "Patra",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sang\u2010Soo",
                "middle": [],
                "last": "Lee",
                "suffix": "",
                "email": "123sslee@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Chiranjib",
                "middle": [],
                "last": "Chakraborty",
                "suffix": "",
                "email": "drchiranjib@yahoo.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "At the end of 2019, a novel coronavirus (SARS\u2010COV\u20102) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei province of China.\n1\n It has a positive\u2010sense single\u2010stranded RNA as their genetic component and shares genome similarity with SARS\u2010CoV and bat coronavirus,\n2\n, \n3\n 79.5% and 96% respectively. Phylogenetically, it belongs to the family Coronaviridae, order Nidovirales and is a \u03b2\u2010coronavirus of 2B group.\n4\n\n",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Regarding epidemiology, human\u2010to\u2010human transmission of the virus through the sneezes, cough, and respiratory droplets has been confirmed, yet the zoonotic nature has not been confirmed.\n5\n, \n6\n, \n7\n Epidemiologic investigation in Wuhan, China identified an initial association with a seafood market where most patients had worked or visited.\n4\n However, as the outbreak progressed, several confirmed cases were reported sporadically all over the world, showing the pandemic nature of the disease named as COVID\u201019. At last, on 30 January 2020, the World Health Organization (WHO) declared this outbreak a public health emergency of international concern.\n8\n According to the situation report 35 (reported by 24 February 2020) of WHO, in China, 77 262 confirmed cases were reported, of which 2595 cases were with deaths. Moreover, outside of China, 2069 confirmed cases were reported in 29 other countries (https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200224-sitrep-35-covid-19.pdf?sfvrsn=1ac4218d_2).",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Therefore, as the situation was getting worse and worse, the need for designing a suitable peptide vaccine component against the SARS\u2010COV\u20102 was growing. Our work was to find suitable epitopes, which can generate enough immune response against the SARS\u2010COV\u20102 infection. Using immunoinformatics, we could recognize and characterize potential B and T\u2010cell epitopes for the generation of the epitopic vaccine against SARS\u2010COV\u20102.\n9\n Specifically, the spike glycoprotein of SARS\u2010COV\u20102 is considered as the target because it forms a characteristic crown of the virus and protrudes from the viral envelope.\n10\n So, the protein sequence of spike glycoprotein was explored thoroughly using multiple immunoinformatic\u2010based servers and software, to identify various epitopes for an effective vaccine.",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "The amino acid sequence of the targeted protein on SARS\u2010COV\u20102 was collected from the National Centre for Biotechnological Information (NCBI) database.\n11\n The protein sequence is very crucial for identifying the potential epitopes of the targeted protein.",
            "cite_spans": [],
            "section": "Collection of targeted protein sequence ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "In this subsection, we used the Immune Epitope Database (IEDB) to identify linear B\u2010cell epitopes using the incorporated BepiPred 2.0 prediction module.\n12\n, \n13\n We provided the FASTA sequence of the targeted protein as an input considering all default parameters.",
            "cite_spans": [],
            "section": "Identification of B\u2010cell epitopes ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "T\u2010cell epitopes having the binding affinity towards MHC\u2010I and MHC\u2010II alleles were selected to boost up both cytotoxic T\u2010cell and helper T\u2010cell mediated immune response. We adopted two servers which are ProPred\u2010I and ProPred server to the selection of MHC\u2010I and MHC\u2010II binding epitopes respectively within preidentified B\u2010cell epitopic region.\n14\n, \n15\n The selected epitopes were submitted to the VaxiJen v.2.0 server applying a virus as a target field with the given threshold value of 0.4 for analyzing the antigenic propensity.\n16\n\n",
            "cite_spans": [],
            "section": "Identification of T\u2010cell epitopes and antigenicity analysis ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "With the help of a specific peptide linker, we fused the antigenic epitopes to construct an effectual vaccine component. Later, the vaccine component was modeled in the SPARKS\u2010X server.\n17\n An adjuvant was also added with the vaccine component to accelerate the adaptive immune responses. The vaccine model passed through two different servers ProSA\u2010web and PROCHECK\u2014in a subsequent manner for evaluating the structural accuracy of the model.\n18\n, \n19\n\n",
            "cite_spans": [],
            "section": "Vaccine construction, modeling, and validation ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Molecular docking is the most promising part of the modern drug\u2010discovery method. Here, in this study, we adopted PatchDock (Beta 1.3 Version) docking server to receptor\u2010ligand docking.\n20\n PatchDock server analyzes the molecular docking between the vaccine component and the toll\u2010like receptor (TLR)\u20105. The generated Protein Data Bank (PDB) file of the protein\u2010peptide docking complex was visualized in PyMOL software v.2.3.\n21\n\n",
            "cite_spans": [],
            "section": "Molecular docking analysis ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Spike glycoprotein of SARS\u2010COV\u20102, retrieved from the NCBI has the GenBank accession ID: QHR63290.1. This spike glycoprotein has 1282\u2010long amino acid sequences and this sequence was downloaded in a FASTA format to carry out the further process.",
            "cite_spans": [],
            "section": "Collection of targeted protein sequence ::: RESULT",
            "ref_spans": []
        },
        {
            "text": "We obtained a total of 34 sequential linear B\u2010cell epitopes of varying lengths from the IEDB server within spike glycoprotein of SARS\u2010COV\u20102. Those B\u2010cell epitopes were placed into Table 1 based on their positional value, sequence, and length. In Figure 1 the yellow\u2010colored peaks represent the epitopic region, while the green\u2010colored slopes, represent the nonepitopic region.",
            "cite_spans": [],
            "section": "Identification of B\u2010cell epitopes ::: RESULT",
            "ref_spans": [
                {
                    "start": 253,
                    "end": 254,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 186,
                    "end": 187,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "We identified 29 MHC\u2010I epitopes and 8 MHC\u2010II epitopes, which fall within the preidentified B\u2010cell epitopic region. Among them, 13 MHC\u2010I epitopes and 3 MHC\u2010II epitopes had the antigenic propensity, according to the VaxiJen v.2.0 server analysis. The MHC\u2010I and MHC\u2010II epitopes are listed in Tables 2 and 3 with encountering MHC alleles and antigenic scores.",
            "cite_spans": [],
            "section": "Identification of T\u2010cell epitopes and antigenicity analysis ::: RESULT",
            "ref_spans": [
                {
                    "start": 296,
                    "end": 297,
                    "mention": "2",
                    "ref_id": "TABREF1"
                },
                {
                    "start": 302,
                    "end": 303,
                    "mention": "3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "In this study, we linked the 13 MHC\u2010I and 3 MHC\u2010II antigenic epitopes with (EAAAK)3 linker peptide to construct a vaccine component. This linker peptide was easily fused with the virus coat protein and increased stability as well as folding of the vaccine component.\n22\n The predicted structure of the vaccine component is shown in Figure 2. It has 90.0%, 7.1%, 1.6%, and 1.3% residues in most favored, additionally allowed, generously allowed and disallowed regions respectively within PROCHECK as the validation server to generate Ramachandran plot. Using the ProSA server, the \u201cZ\u201d score was \u22123.82 and most of the residues had negative energy value as shown in Figure 3. Results from both servers indicate the model is in a good quality.\n23\n, \n24\n\n",
            "cite_spans": [],
            "section": "Vaccine construction, modeling, and validation ::: RESULT",
            "ref_spans": [
                {
                    "start": 339,
                    "end": 340,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 670,
                    "end": 671,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "The PatchDock server provided 20 docking complexes, and among them, we selected only the docking complex with the highest negative atomic contact energy (ACE) value for analysis. The ACE value of the docking complex was \u2212259.62, which indicates spontaneous reactivity between the vaccine component and TLR\u20105.\n25\n As proper protein\u2010protein docking regulates the cellular functions, the docking between the vaccine component and TLR\u20105 will activate immune cascades for destroying the viral antigens.\n26\n The selected docking complex is shown in Figures 4 and 5, along with molecular surface interaction as well as some bonding interactions.",
            "cite_spans": [],
            "section": "Molecular docking analysis ::: RESULT",
            "ref_spans": [
                {
                    "start": 551,
                    "end": 552,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                },
                {
                    "start": 557,
                    "end": 558,
                    "mention": "5",
                    "ref_id": "FIGREF4"
                }
            ]
        },
        {
            "text": "The SARS\u2010COV\u20102, the causative pathogen for respiratory distress syndrome, led more than 10 000 people to infection all over the world, even several to death. After first identified in Wuhan, Hubei province of China, the COVID\u201019 disease spread unchecked which finally became a global threat. Scientists from all over the world are struggling to find a solution to this evil outbreak.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "In our present study, we attempted to find out various B\u2010cell and T\u2010cell epitopes against SARS\u2010COV\u20102, using the immunoinformatics, as quick identification of B\u2010cell and T\u2010cell epitopes is crucial for designing of vaccine component against this disease. The spike glycoprotein was analyzed for B\u2010cell epitope identification in the IEDB server, and 34 linear B\u2010cell epitopes were identified as a result. Subsequently, the sequence was also analyzed in ProPred\u2010I and ProPred servers for the identification of the T\u2010cell epitope that can combine with MHC\u2010I and MHC\u2010II molecules. Fortunately, we found 29 epitopes against MHC\u2010I and 8 epitopes against MHC\u2010II that can be possibly used for vaccine. Unfortunately, antigenic characterization in VaxiJen v.2.0 discarded 16 MHC\u2010I epitopes out of 29 and 5 out of 8 MHC\u2010II epitopes as these seemed to be nonantigenic in nature. Nevertheless, we converted the antigenic epitopes into a single vaccine component, using (EAAAK)3 peptide linker.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Later, the vaccine component was modeled in the SPARK\u2010X server and validated in PROCHECK and ProSA. A total of 90% of nonglycine and nonproline residues presented within the most favored region, while the \u201cZ\u201d score of the model was \u22123.82. These results from both servers indicate the model is in good quality. Molecular docking between vaccine component and TLR\u20105 showed significant ACE value, which indicates spontaneous reactivity within the receptor\u2010ligand complex.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "All the observations of our present work depict the effectiveness of selected epitopes within the spike glycoprotein of SARS\u2010COV\u20102. These epitopes can be used to make an immunogenic multi\u2010epitopic peptide vaccine against SARS\u2010COV\u20102.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Present immunoinformatic analysis pointed out 13 MHC\u2010I and 3 MHC\u2010II epitopes within the spike glycoprotein of SARS\u2010COV\u20102. These epitopes are the ideal candidate to formulate a multi\u2010epitopic peptide vaccine, not only because of being selected from the linear B\u2010cell epitopic region but also because of their antigenic property was confirmed. Moreover, the molecular docking of vaccine components with the TLR\u20105 proves the significance and effectiveness of these epitopes as an ideal vaccine candidate against SARS\u2010COV\u20102. However, these immunoinformatic analyses require several in vitro and in vivo validations before formulating the vaccine to resist COVID\u201019.",
            "cite_spans": [],
            "section": "CONCLUSION",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: List of linear B\u2010cell epitopes along with their sequence, position, and length\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: List of epitopes with encountering MHC\u2010I alleles, positional value, and VaxiJen antigenic score\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: List showing the epitopes with encountering MHC\u2010II alleles, positional value and VaxiJen antigenic score\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: Graphical representation of linear B\u2010cell epitopes within the spike glycoprotein of SARS\u2010COV\u20102",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: Tertiary structural model of construct vaccine component",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: Different molecular characterization of vaccine model. (a) All atoms at Ramachandran plot, (b) \u201cZ\u201d score plot of vaccine model in ProSA server, and (c) all residue energy plot",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure 4: Docking complex exhibiting the surface interaction between vaccine component (cyan color) and toll\u2010like receptor\u20105 (green color)",
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Figure 5: Docking complex exhibiting the bonding interaction between vaccine component and toll\u2010like receptor\u20105",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "A novel coronavirus outbreak of global health concern",
            "authors": [],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "",
            "pages": "470-473",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
            "authors": [],
            "year": 2020,
            "venue": "Nature",
            "volume": "",
            "issn": "",
            "pages": "1-4",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "A novel coronavirus from patients with pneumonia in China, 2019",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "",
            "pages": "727-733",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "The continuing 2019\u2010nCoV epidemic threat of novel coronaviruses to global health\u2014the latest 2019 novel coronavirus outbreak in Wuhan, China",
            "authors": [],
            "year": 2020,
            "venue": "Int J Infect Dis",
            "volume": "91",
            "issn": "",
            "pages": "264-266",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person\u2010to\u2010person transmission: a study of a family cluster",
            "authors": [],
            "year": 2020,
            "venue": "The Lancet",
            "volume": "395",
            "issn": "",
            "pages": "514-523",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Novel Wuhan (2019\u2010nCoV) coronavirus",
            "authors": [],
            "year": 2020,
            "venue": "Am J Respir Crit Care Med",
            "volume": "201",
            "issn": "",
            "pages": "P7-P8",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Another decade, another coronavirus",
            "authors": [],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "382",
            "issn": "8",
            "pages": "760-762",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "The Novel coronavirus originating in Wuhan, China: challenges for global health governance",
            "authors": [],
            "year": 2020,
            "venue": "JAMA",
            "volume": "323",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "A novel multi\u2010epitope recombined protein for diagnosis of human brucellosis",
            "authors": [],
            "year": 2016,
            "venue": "BMC Infect Dis",
            "volume": "16",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "CT imaging features of 2019 novel coronavirus (2019\u2010nCoV)",
            "authors": [],
            "year": 2020,
            "venue": "Radiology",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Database resources of the National Center For Biotechnology Information",
            "authors": [],
            "year": 2016,
            "venue": "Nucleic Acids Res",
            "volume": "44",
            "issn": "database issue",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Immune epitope database analysis resource",
            "authors": [],
            "year": 2012,
            "venue": "Nucleic Acids Res",
            "volume": "40",
            "issn": "W1",
            "pages": "W525-W530",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "BepiPred\u20102.0: improving sequence\u2010based B\u2010cell epitope prediction using conformational epitopes",
            "authors": [],
            "year": 2017,
            "venue": "Nucleic Acids Res",
            "volume": "45",
            "issn": "W1",
            "pages": "W24-W29",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "ProPred1: prediction of promiscuous MHC Class\u2010I binding sites",
            "authors": [],
            "year": 2003,
            "venue": "Bioinformatics",
            "volume": "19",
            "issn": "8",
            "pages": "1009-1014",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "ProPred: prediction of HLA\u2010DR binding sites",
            "authors": [],
            "year": 2001,
            "venue": "Bioinformatics",
            "volume": "17",
            "issn": "12",
            "pages": "1236-1237",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines",
            "authors": [],
            "year": 2007,
            "venue": "BMC Bioinformatics",
            "volume": "8",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Improving protein fold recognition and template\u2010based modeling by employing probabilistic\u2010based matching between predicted one\u2010dimensional structural properties of query and corresponding native properties of templates",
            "authors": [],
            "year": 2011,
            "venue": "Bioinformatics",
            "volume": "27",
            "issn": "15",
            "pages": "2076-2082",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "ProSA\u2010web: interactive web service for the recognition of errors in three\u2010dimensional structures of proteins",
            "authors": [],
            "year": 2007,
            "venue": "Nucleic Acids Res",
            "volume": "35",
            "issn": "suppl_2",
            "pages": "W407-W410",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "PROCHECK: validation of protein\u2010structure coordinates",
            "authors": [],
            "year": 2006,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "PatchDock and SymmDock: servers for rigid and symmetric docking",
            "authors": [],
            "year": 2005,
            "venue": "Nucleic Acids Res",
            "volume": "33",
            "issn": "suppl_2",
            "pages": "W363-W367",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Pymol: an open\u2010source molecular graphics tool",
            "authors": [],
            "year": 2002,
            "venue": "CCP4 Newsletter on protein crystallography",
            "volume": "40",
            "issn": "1",
            "pages": "82-92",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Fusion protein linkers: property, design and functionality",
            "authors": [],
            "year": 2013,
            "venue": "Adv Drug Deliv Rev",
            "volume": "65",
            "issn": "10",
            "pages": "1357-1369",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "A homology model for Clostridium difficile methionyl tRNA synthetase: active site analysis and docking interactions",
            "authors": [],
            "year": 2011,
            "venue": "J Mol Model",
            "volume": "17",
            "issn": "7",
            "pages": "1679-1693",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Biocomputational analysis and in silico characterization of an angiogenic protein (RNase5) in zebrafish (Danio rerio)",
            "authors": [],
            "year": 2019,
            "venue": "Int J Pept Res Ther",
            "volume": "",
            "issn": "",
            "pages": "1-11",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "In silico identification of catalytic residues in azobenzene reductase from Bacillus subtilis and its docking studies with azo dyes",
            "authors": [],
            "year": 2009,
            "venue": "Interdiscip Sci: Comput Life Sci",
            "volume": "1",
            "issn": "4",
            "pages": "290-297",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Detection of peptide\u2010binding sites on protein surfaces: The first step toward the modeling and targeting of peptide\u2010mediated interactions",
            "authors": [],
            "year": 2013,
            "venue": "Proteins: Struct, Funct, Bioinf",
            "volume": "81",
            "issn": "12",
            "pages": "2096-2105",
            "other_ids": {
                "DOI": []
            }
        }
    }
}